Galectins are ␤-galactoside-binding lectins that are involved in various biologic processes, such as apoptosis, cell proliferation, and cell-cycle regulation. Galectin-9 (Gal-9) was identified previously and demonstrated to have apoptotic potential to thymocytes in mice and activated CD8 ؉ T cells in nephrotoxic serum nephritis model. In this study, the effect of Gal-9 on G1-phase cell-cycle arrest, one of the hallmark pathologic changes in early diabetic nephropathy, was investigated. Eightweek-old male db/db mice received injections of recombinant Gal-9 or vehicle for 8 wk. The injection of Gal-9 into db/db mice significantly inhibited glomerular hypertrophy and mesangial matrix expansion and reduced urinary albumin excretion. Gal-9 reduced glomerular expression of TGF-␤1 and the number of p27 Kip1 -and p21 Cip1 -positive cells in glomeruli. Double staining with nephrin and type IV collagen revealed that podocytes were mainly positive for p27 Kip1 . For further confirming the cell-cycle regulation by Gal-9, conditionally immortalized mouse podocyte cells were cultured under 5.5 and 25 mM D-glucose supplemented with Gal-9. Cell-cycle distribution analyses revealed that Gal-9 maintained further progression of cell cycle from the G1 phase. Gal-9 reversed the high-glucose-mediated upregulation of p27
G
alectins are a family of carbohydrate-binding proteins that have specific binding affinity for ␤-galactosides, and they exhibit evolutionary conservation from fungi to mammals (1, 2) . Their characteristic structural features across species are the presence of one or two carbohydrate recognition domains (CRD) that bind to ␤-galactosides and consist of approximately 130 amino acids (3) . To date, 14 galectins have been identified in mammals (1) , and their conserved structural characteristics of galectins among various family members suggest an essential role in a wide variety of biologic processes, such as cellular adhesion, migration, chemotaxis, proliferation, apoptosis, and differentiation (4, 5) . Furthermore, their roles have been implicated in several pathobiologic processes, including autoimmune (6 -9) and allergic disorders (10, 11) , inflammation (12, 13) , tumor spreading (14 -17) , atherosclerosis, and various complications of diabetes (18 -20) .
Galectins can be divided into three groups on the basis of their structural features (1) monovalent galectins that contain a single CRD that forms homodimers and acts as bivalent functionally active molecules, (2) bivalent tandem repeat galectins that have two CRD that are connected with a unique link peptide, (3) chimeric galectins that have a single CRD with a unique amino terminus that contributes to their functional activity (1) (2) (3) . Previously, we identified a mouse and rat galectin-9 (Gal-9), which is a member of tandem repeat type (21) , and its human homologue was independently cloned by other investigators using autoreactive antibody found in Hodgkin's disease (22) . The Gal-9 is primarily expressed in tissues of the immune system, such as thymus, lymph nodes, spleen, and bone marrow. During a given immune response, it also gets expressed in various cell types in the tissues that are infiltrated by T cells, such as endothelia, fibroblasts, lung epithelial cells, and cardiac myocytes (21, 23) . We demonstrated previously that recombinant Gal-9 protein induces apoptosis, suggesting a role in negative selection of autoreactive T cells (23) . Furthermore, Gal-9 induced apoptosis in activated CD8 ϩ T cells in Wistar
Kyoto rats with glomerulonephritis (9) . It is interesting that Gal-1 is also expressed in the cortical thymic epithelial cells, and it selectively induces apoptosis in activated thymocytes while leaving the resting T cells unaffected (24 -26) , suggesting a potential mechanism to eliminate activated T cells at the termination of the immune response (4) . Gal-1 also induces apoptosis in B cells (24, 27) . Other galectins that exert a pro-apoptotic effect in various cell types include Gal-7 in keratinocytes (28, 29) , Gal-8 in cancer cells (30) , and Gal-12 in adipocytes and neoplastic cells (31) (32) (33) . However, Gal-3 has an antiapoptotic effect in T cells and breast cancer cells (34, 35) . In terms of cell-cycle regulation, Gal-1 has no significant effect in normal cells, and it acts as a negative cell-cycle regulator in T cells (15, 36) and induces proliferation of endothelial cells and fibroblasts (37, 38) . In contrast, Gal-1 causes S/G2 cell-cycle arrest and apoptosis in various cancer cells, such as of breast and neural tissues (15) . In view of the above biologic effects of various galectins, it is conceivable that Gal-9 may act as an essential cell-cycle regulator. At present, there are numerous ongoing studies investigating the effect of galectins on cell cycle in various cancer cells. The cell cycle is dysregulated in the diabetic state, and G1-phase arrest is believed to be responsible for the high-glucoseinduced cellular hypertrophy and increase in the de novo protein synthesis and consequential accumulation of extracellular matrix proteins, as typically seen in diabetic nephropathy (39, 40) . There is a growing body of evidence that specific cyclindependent kinase (CDK) inhibitors, p27
Kip1 and p21 Cip1 , are critically involved in hypertrophy of mesangial cells that are exposed to high glucose ambience (41, 42) and in experimental type 1 and 2 diabetes (43, 44) and also in p27
Kip1 knockout (45) . The inhibition of TGF-␤-mediated hypertrophy in cultured mesangial cells derived from p27
Kip1 and p21 Cip1 double null (Ϫ/Ϫ) mice also support the notion that CDK inhibitors are critical molecules in cellular hypertrophy (46) . Our study describes the ameliorative effect of the Gal-9 on the progression of diabetic nephropathy in db/db mice, which seems to be related to its modulation of the cell cycle via CDK inhibitors: p27 Kip1 and p21
Cip1 .
Materials and Methods

Animals and Experimental Protocol
Eight-week-old male db/db mice that lack the hypothalamic leptin receptor (47) , a model of type 2 diabetes, were purchased (Clea Co. Ltd., Tokyo, Japan) and were used for various studies. These mice manifest hyperglycemia, hyperinsulinemia, hyperleptinemia, hyperlipidemia, and obesity commencing at 4 to 6 wk of age and albuminuria at 6 wk after birth (48, 49) . The db/db mice were divided into two groups: Diabetic db/db mice that were treated with PBS that contained 1 mM dithiothreitol (DTT; PBS-DTT buffer; db/db, n ϭ 10) and db/db mice that were treated with recombinant Gal-9 in PBS-DTT buffer (db/db ϩ Gal-9, n ϭ 10). Nondiabetic db/m mice were also divided into two groups: db/m mice that were treated with PBS-DTT buffer (db/m, n ϭ 10) or treated with recombinant Gal-9 in PBS-DTT buffer (db/m ϩ Gal-9, n ϭ 10). Gal-9 (1 mg/kg) or PBS-DTT buffer was administered intraperitoneally three times a week for a period of 8 wk, and the animals were killed at 16 wk of age. Blood and tissue samples were harvested and processed for various studies. Blood samples were collected from tail vein after a 12-h fast. The mice were placed in individual metabolic cages for 24-h urine collection. BP was measured by tail-cuff method (BP-98A; Softron Corp., Tokyo, Japan).
Biochemical Analyses
Blood glucose, hemoglobin A1c, serum creatinine, plasma insulin, and daily urinary albumin excretion were measured at 8, 12, and 16 wk of age. Total cholesterol, triglyceride, and free fatty acid levels were also measured at 16 wk of age. Urinary albumin concentration was measured by nephelometry (Organon Teknika-Cappel, Durham, NC) and insulin levels were measured by RIA (Linco Research Inc., St. Charles, MO).
Preparation of Recombinant Mouse Gal-9
Production of recombinant mouse Gal-9 was carried out using pTrcHis2 vector (Invitrogen, San Diego, CA) as described previously (9, 21, 23) . After pTrcHis2/G9 was transformed into the TOP10 bacterial host (Invitrogen), a single colony was picked and grown in LuriaBertani's medium. Protein synthesis was induced with the addition of 1 mmol/L isopropyl-␤-d-thiogalacto-pyranoside (Sigma, St. Louis, MO). The cell pellets were lysed in PBS that contained 1 mM DTT, 1.25% Triton X-100, 10 mM benzamidine, 10 mM ⑀-amino-n-caproic acid, and 2 mM PMSF. Supernatants were applied to a 15-ml lactosylSepharose column (Sigma) and eluted with PBS that contained 1 mM DTT and 200 mmol/L lactose. The eluted fractions were collected and dialyzed against PBS buffer that contained 1 mM DTT. The endotoxin concentration in the purified Gal-9 was Ͻ10 EU/mg proteins, as assessed by Limulus Amoebocyte Lysate Assay (Seikagaku Corp., Tokyo, Japan).
Morphologic Studies
Renal tissues were fixed in 10% paraformaldehyde and embedded in paraffin, and 4-m-thick sections were prepared. The sections were stained with periodic acid-Schiff (PAS). Glomerular tuft and mesangial matrix area were measured with image analysis software (Optimas version 6.5; Media Cybernetics, Silver Spring, MD). The cross-section that yielded the maximum diameter of the glomerulus was photographed and converted into a digital image, and ultrastructural examination of the glomeruli was carried out using tissues that were processed for electron microscopy (50) .
Immunohistochemistry
Four-micrometer-thick sections of formalin-fixed, paraffin-embedded tissues were deparaffinized and rehydrated, and endogenous peroxidase was blocked by incubation in 3% hydrogen peroxide and methanol. Sections were pretreated by microwave for 20 min in citrate buffer for antigen retrieval. Nonspecific binding was blocked by incubation for 30 min in 10% rabbit serum. The tissues then were incubated with anti-p27 Kip1 Digital images were obtained using confocal laser fluorescence microscope (LSM-510; Carl Zeiss, Jena, Germany), and type IV collagen expression was quantified with the formula (density indicated by 0 to 255 in gray scale ϫ positive area m 2 ) as described previously (51) .
Northern Blotting and Quantitative Real-Time PCR
Total RNA was isolated from kidney tissue of mice and cells using QIAzol Reagent (Qiagen, Hilden, Germany). Twenty micrograms of total RNA was subjected to 2.2 M formaldehyde 1% agarose gel electrophoresis, and capillary was transferred to the Hybond XL nylon membranes (Amersham Biosciences, Piscataway, NJ). The membranes were hybridized with [␣-
32 P]dCTP-radiolabeled mouse ␣1(IV) collagen, ␣5(IV) collagen, TGF-␤1, VEGF, and human ␤-actin (1 ϫ 10 6 cpm/ml) cDNA (American Type Culture Collection [ATCC], Rockville, MD) at 68°C in ExpressHyb Hybridization Solution (Clontech, Palo Alto, CA) for 1 h. Filters were washed at high stringency conditions (four times in 1ϫ SSC/0.1% SDS at 20°C, followed by two times at 50°C in 0.1ϫ SSC/0.1% SDS). Autoradiogram was prepared using Bio-Imaging Analyzer System (BAS-1800II; FujiFilm, Tokyo, Japan). For quantitative real-time PCR analysis, cDNA were synthesized from 1 g of total RNA and analyzed using LightCycler-FastStart DNA master SYBR Green I system (Roche Diagnostic Co., Basel, Switzerland) and specific primers. The relative abundance of mRNA was standardized with ␤-actin mRNA as the invariant control. The primers used were as follows: Mouse TGF-␤1 5Ј-AACAACGCCATCTATGAG-3Ј and 5Ј-TATTCCGTCTCCTTGGTT-3Ј (Nihon Gene Research Lab's Inc., Sendai, Japan).
Cell Culture
For propagating mouse podocyte cell (MPC) lines (gift from Prof. Peter Mundel, Albert Einstein College of Medicine, Bronx, NY) (52), the cells were cultured on type I collagen-coated flasks (BD Falcon, San Jose, CA) with RPMI 1640 (Invitrogen, Carlsbad, CA) that contained 10% FCS (Invitrogen) and 50 U/ml recombinant mouse IFN-␥ (BD Biosciences, Palo Alto, CA) at 33°C. After 90% confluence, the cells were induced to differentiate into podocyte lineage by shifting them to 37°C and culturing in DMEM (Sigma, St. Louis, MO) that contained 10% FCS (Invitrogen) without IFN-␥, i.e., nonpermissive conditions. After 7 d of culture of MPC under nonpermissive conditions, the cells were further cultured in DMEM that contained 0.5% FCS (Invitrogen) for 48 h, and quiescent mature podocytes were incubated with 5.5 mM normal glucose with PBS-DTT buffer (NG), NG with 1 M Gal-9 (NGϩGal-9), 25 mM high glucose with PBS-DTT buffer (HG), HG with 1 M Gal-9 (HGϩGal-9), and NG with 19.5 mM mannitol (MN) for 6 d. They then were subjected to the following studies: Cell cycle analysis, Murine mesangial cell line (MES 13) was purchased from the (ATCC, Rockville, MD). Cells were cultured in DMEM that contained 10% FCS at 37°C. After subconfluence, cells were starved for 24 h by incubating them in DMEM that contained 0.5% FCS. Quiescent cells were incubated with 5.5 mM NG, NGϩGal-9, 25 mM HG, HGϩGal-9, and NG with MN for 2 d. They then were subjected to [ 3 H]thymidine and 
Measurement of Cell Number and Cellular Protein
Cells were washed with PBS and trypsinized for counting the cell number in a Coulter counter (model Z1; Beckman Coulter, Fullerton, CA) with 100-m aperture (Beckman Coulter). Cells were also lysed, and the total protein content was determined by Lowry method (Biorad, Hercules, CA).
Western Blotting
At the end of MPC and MES culture, cells were washed with PBS and lysed with a buffer (20 mM Tris-HCl [pH 7.4], 100 mM NaCl, 10 mM benzamidine-HCL, 10 mM ⑀-amino-n-caproic acid, 2 mM PMSF, and 1% Triton X-100). Forty micrograms of protein was subjected to SDS-PAGE under reducing conditions and electroblotted onto Hybond P polyvinylidene difluoride membranes (Amersham Biosciences). The membrane blots were immersed in a blocking solution that contained 5% nonfat dry milk and TBS-T (0.05% Tween 20, 20 mM Tris-HCl, and 150 mM NaCl [pH 7.6]). Then, membranes were incubated individually with rabbit polyclonal anti-p27 Kip1 (1:100 dilution), anti-p21 Cip1 (1:100 dilution; Santa Cruz Biotechnology), and anti-actin antibody (1:500 dilution; Sigma). They then were incubated with anti-rabbit IgG conjugated with horseradish peroxidase (1:20,000 dilution; Amersham) for polyclonal antibodies and anti-mouse IgG conjugated with horseradish peroxidase (1:20,000 dilution; Amersham) for monoclonal antibodies. The blots then were washed three times with TBS-T, immersed in ECL Plus Western Blotting Detection Reagents (Amersham), and then exposed to Hyperfilm ECL (Amersham).
Cell-Cycle Analysis by Laser Scanning Cytometry
MPC seeded on type I collagen-coated chamber slides (BD Falcon) were fixed with 100% ethanol for 15 min. The cells were treated with 200 g/ml DNAse free-RNase A (Sigma) for 15 min at 37°C, and then nuclear DNA was stained with 50 g/ml propidium iodide (Sigma) in the dark. Stained cells were analyzed with a laser scanning cytometer (Olympus Optical Co. Ltd., Tokyo, Japan) by measuring total and peak intensity of propidium iodide fluorescence in each nucleus (53) . We analyzed approximately 3000 unperturbed MPC populations and generated a detailed profile of the cell cycle, i.e., percentage of the cells in G0/G1, S, G2, and M. Cell-cycle analysis was performed independently three times.
Statistical Analyses
Data were expressed as the mean Ϯ SEM and analyzed by unpaired t test or a one-way ANOVA by Fisher t test when multiple comparisons against the control were required. We used 2 test with Yates correction for 2 ϫ 2 tables to compare the categorical data. P Ͻ 0.05 was regarded as statistically significant. The data were analyzed with Dr. SPSS II for Windows release 11.0.1J.
Results
Administration of Gal-9 Reduces Urinary Albumin Excretion in db/db Mice
The baseline (8 wk of age) and final (16 wk of age) body weights of db/db mice were significantly greater than those of db/m mice ( Table 1 ). The increase in body weight over the experimental period was similar in db/db mice and the db/dbϩGal-9 group. There were no significant differences in BP among four groups throughout the study period. The diabetic db/db mice remained hyperglycemic, and hemoglobin A1c levels were significantly higher in db/db mice compared with db/m littermates. At the end of the study, db/db mice had significant hyperinsulinemia and increased levels of cholesterol and free fatty acid compared with db/m mice. The administration of Gal-9 did not alter the glucose levels and lipid profile in db/db mice. The final kidney weight was significantly higher in db/db compared with db/m mice, and renal hypertrophy was ameliorated in Gal-9 -treated db/db mice. However, the average kidney-to-body weight ratios were higher in db/m mice, and there were no statistically significant differences between db/db mice and db/dbϩGal-9 mice, because diabetic db/db mice were much heavier than db/m littermates. Urinary albumin excretion was significantly increased in db/db mice compared with db/m mice at 12 and 16 wk of age. Gal-9 treatment significantly reduced urinary albumin excretion in db/db mice at 12 and 16 wk of age (Figure 1 ).
Gal-9 Infusion Ameliorates Glomerular Hypertrophy in db/db Mice
At the end of the study, PAS-positive mesangial matrix area and glomerular size of db/db mice were significantly increased compared with db/m mice (Figure 2, A through D) . Morphometric analysis clearly indicated that Gal-9 significantly reduced both glomerular cross-sectional area and the mesangial matrix index, i.e., the ratio of mesangial matrix area divided by the tuft area (Figure 2, E and F) . The infusion of Gal-9 into db/m mice revealed no effects on the electron microscopic findings (Figure 3, A and B) . Amelioration in the mesangial expansion by Gal-9 treatment was confirmed by electron microscopic examination (Figure 3, D and F) . In addition, the cellular hypertrophy, especially in podocytes, was noted in db/db mice ( Figure 3C ), whereas such hypertrophic changes in glomeruli were not observed in db/db mice that were treated with Gal-9 ( Figure 3E ).
Gal-9 Infusion Reduced Expression of ␣1 (IV) and ␣5 (IV) Collagen and TGF-␤1 but not VEGF Proteins
Northern blot analyses of kidney cortex revealed that ␣1 (IV) and ␣5 (IV) collagen mRNA levels were significantly increased, more than four-fold in db/db mice compared with db/m mice ( Figure 4, A and B) . Gal-9 treatment prevented the increase in ␣1 (IV) and ␣5 (IV) collagen mRNA expressions in db/db mice. Figure 1 . Injection of galectin-9 (Gal-9) reduces albuminuria in diabetic mice. ELISA specific for mouse albumin was used to evaluate 24-h urine albumin excretion. The increased excretion of albumin in db/db mice is reduced at 12 and 16 wk of age by repeated injection of recombinant Gal-9. Data are mean Ϯ SEM; *P Ͻ 0.01 versus db/m mice; **P Ͻ 0.05 versus db/db mice. Besides mRNA expression of type IV collagen chains, the immunofluorescence intensity of type IV collagen quantified by morphometric analysis also showed the accumulation of type IV collagen in glomeruli was significantly reduced with the treatment of Gal-9 ( Figure 4 , C through F and K). mRNA expression of growth factors that mediate the progression of diabetic nephropathy, i.e., TGF-␤1 and VEGF, also significantly upregulated in db/db mice compared with db/m mice ( Figure 4 , A and B). However, the treatment with Gal-9 did not alter the mRNA expression of TGF-␤1 and VEGF in renal cortex. We examined the expression level of TGF-␤1 and VEGF proteins in renal glomeruli by using immunohistochemistry. TGF-␤1 protein levels in renal glomeruli increased in diabetic db/db mice compared with control db/m mice. Gal-9 treatment significantly inhibited the glomerular expression of TGF-␤1 protein in diabetic db/db mice ( Figure 4 , G through J and L). VEGF protein levels in renal glomeruli increased in diabetic db/db mice compared with control db/m mice. However, Gal-9 treatment revealed no effect on the expression of VEGF protein in diabetic db/db mice (data not shown).
Gal-9 Decreased Glomerular p27 Kip1 -and p21 Cip1 -Positive Cells in db/db Mice
To gain insight into the ameliorative effect of Gal-9 on diabetic nephropathy, we evaluated expression of CDK inhibitors p27 Kip1 and p21 Cip1 ( Figure 5 , A through H). Glomerular p27
Kip1 -and p21 Cip1 -positive cells were significantly increased in db/db mice compared with db/m mice ( Figure 5 , I and J). Although tubular cells revealed positive staining for p27 Kip1 and p21
Cip1 , there was no significant difference between db/db and db/m mice (data not shown). The treatment with Gal-9 recombinant protein significantly reduced both p27
Kip1 -and p21
Cip1 -positive glomerular cells ( Figure 5 , D and H). To identify which glomerular cells are associated with positive nuclear staining of p27 Kip1 , we investigated the expression of p27 Kip1 , nephrin, and type IV collagen using double immunofluorescence studies. p27
Kip1 -positive glomerular cells were mainly observed in extracapillary space and adjunct with capillary lining, which was visualized by nephrin and type IV collagen immunostaining ( Figure 5K ). Although part of the mesangial and glomerular cells were also positive for p27 Kip1 , we demon- 
Galectin-9 Reduces High-Glucose-Induced Protein Synthesis of MPC
To assess cellular hypertrophy/hyperplasia of MPC and MES, we assessed DNA and protein synthesis by [ 3 H]thymidine and [
3 H]proline incorporation. In MPC culture, [ 3 H]thymidine incorporation and cell number were unaffected with NG, HG, or MN, and treatment with Gal-9 also showed no effect on [ 3 H]thymidine incorporation ( Figure 6 , A and C). In contrast, high glucose increased de novo protein synthesis, i.e., [ 3 H]proline (dpm/cellular protein (g), and Gal-9 reduced protein synthesis and total cellular protein ( Figure 6, B and D) . In MES culture, [ 3 H]thymidine incorporation and cell number under high-glucose conditions was significantly reduced compared with NG, NGϩGal-9, and MN, and treatment with Gal-9 showed partial recovery of [ 3 H]thymidine incorporation and cell number without statistical significance (Figure 6 , E and G). 
Gal-9 Reduces p27 Kip1 and p21 Cip Expression in MPC Culture
In MPC culture, high glucose significantly upregulated both p27
Kip1 and p21 Cip1 protein levels. To investigate dose-dependent effects of Gal-9, we included various concentration of Gal-9 into culture media and examined the expression levels of p27 Kip1 and p21 Cip1 protein under high-glucose conditions. Gal-9 inhibited the expression of p27
Kip1 and p21 Cip1 protein in a dose-dependent manner, and maximal inhibitory effects were observed under the concentration of 1 M Gal-9 ( Figure 7A ). Treatment with 1 M Gal-9 significantly reduced the expression of p27
Kip1 and p21 Cip1 protein under high-glucose conditions, whereas hyperosmotic stimulus with MN did not change the expression of p27
Kip1 and p21 Cip1 ( Figure 7B ). High glucose increased the mRNA level of TGF-␤1 without statistical significance, and Gal-9 showed no effect on the expression of TGF-␤1 mRNA ( Figure 7C) .
In MES culture, high glucose significantly upregulated both p27
Kip1 and p21 Cip1 protein levels. The treatment with 1 M Gal-9 showed some inhibitory effects on high-glucose-induced upregulation of p27 Kip1 , p21 Cip1 ( Figure 7B ), and TGF-␤1 mRNA ( Figure 7C) ; however, they did not enter the statistical differences.
Gal-9 Progresses Cell Cycle in MPC with High-GlucoseInduced G1 Cell-Cycle Arrest
To investigate whether Gal-9 affects high-glucose-induced cell-cycle arrest in vitro, we cultured differentiated MPC in DMEM that contained 0.5% FCS for 48 h, and quiescent mature podocytes were incubated with NG, NG with 1 M Gal-9, HG, HG with 1 M Gal-9, and MN for 6 d. The cell-cycle distribution of MPC then was analyzed by laser scanning cytometer after staining with propidium iodide (Figure 8 ). After serum deprivation, approximately 94% of MPC in HG was in G0/G1 phase, approximately 2% in the S phase, and approximately 3% in G2 phase, whereas approximately 89% of MPC were in the G0/G1 phase under NG (Figure 8 ). Incubation with recombinant Gal-9 altered cell-cycle distribution and reduced cell arrest in the G0/G1 phase (approximately 92% in G0/G1, approximately 3% in the S, approximately 5% in the G2; Figure 8 ). 2 test with Yates correction for 2 ϫ 2 tables, categorized with G0/G1 versus S/G2/M, indicated that G0/G1 significantly increased in HG compared with NG (P Ͻ 0.05) and significantly decreased in HG compared with 1 M Gal-9 and compared with HG (P Ͻ 0.05).
Discussion
Morphometric analyses on renal specimens from patients with types 1 and 2 diabetes reveal characteristic cell hypertrophy, in particular of mesangial cells in early stages of diabetic nephropathy (39, 40) . Hypertrophy is defined as an increase in protein synthesis without DNA replication (39, 40) . High glu- Figure 3 . Gal-9 prevents glomerular cell hypertrophy. Electron microscopic photographs from db/m mice with vehicle (A), db/m mice that were treated with Gal-9 (B), db/db mice with vehicle (C and D), and db/db mice that were treated with Gal-9 (E and F). The alteration of the morphology of kidneys is not seen by the treatment of Gal-9 in db/m mice (A and B). Prominent hypertrophy of podocytes (C) and mesangial cells (D) is noted in db/db mice. By repeated treatment with Gal-9, such hypertrophic changes are markedly reduced in both podocytes and mesangial cells (E and F). Accumulation of mesangial matrix observed in db/db mice (D) seems also to be prevented (F). Figure 4 . Gal-9 reduces gene expression of ␣1 (IV) and ␣5 (IV) collagens in renal cortex and protein expression of type IV collagens and TGF-␤1 expression in renal glomeruli. Representative Northern blot is shown (A), and densitometric analyses are shown (B). The injections of Gal-9 significantly reduce mRNA expression of ␣1 (IV) and ␣5 (IV) collagen; however, TGF-␤1, and VEGF mRNA expression is unaltered. By immunofluorescence microscopy, the intensity of type IV collagen signal significantly increases in glomeruli in db/db mice compared with db/m mice (E and C). Gal-9 treatment significantly reduces intensity of type IV collagen (E, F, and K). By immunohistochemistry, TGF-␤1 protein levels in renal glomeruli increase in diabetic db/db mice compared with control db/m mice (G and I). Gal-9 treatment significantly inhibits the glomerular expression of TGF-␤1 protein in diabetic db/db mice (I, J, and L). Data are mean Ϯ SEM; *P Ͻ 0.01 versus db/m mice; **P Ͻ 0.01 versus db/db mice. cose stimulates the expression of TGF-␤1 (46,54) and connective tissue growth factor (41,55) during mesangial cell hypertrophy, a well-recognized hallmark of diabetic nephropathy (39) . The upregulated expression of TGF-␤1 leads to increased transcriptional activity of cyclin D and induction of CDK inhibitors through transcriptional and posttranslational mechanisms. Although mesangial cells can reenter the cell cycle, they fail to progress through G1/S phase because of the induction of CDK inhibitors. Besides mesangial cells, recent studies have demonstrated that podocyte hypertrophy is observed in differentiated podocyte cell line and Zucker fatty rats (56) . In addition, increase in p21
Cip1 and p27 Kip1 has been described in podocytes in Zucker fatty rats, which is also seen in db/db mice in our studies (56) . In type 1 and 2 diabetes, a decrease in podocyte number is well correlated with both microalbuminuria and progression of diabetic nephropathy (57) . High glucose induces the expression of TGF-␤1, and it in turn stimulates the expression of the CDK inhibitors p21
Cip1 and p27 Kip1 , although highglucose-mediated induction of p27
Kip1 is to some extent independent of TGF-␤1 pathway (58) . Thus, one can conclude that high-glucose-mediated podocyte injury associated with G1-phase cell-cycle arrest seems to be another major player in the pathogenesis of diabetic glomerulopathy.
In db/db mice, chronic administration of Gal-9 reduced albuminuria and inhibited glomerular hypertrophy and accumulation of extracellular matrix. Injection of Gal-9 inhibited both Cip1 are expressed in nuclei of glomerular and tubular epithelial cells (A and E). In db/db mice, p27 Kip1 -and p21 Cip1 -positive cells are seen predominantly in podocytes, and the ratio is significantly higher than in db/m mice (A, C, E, G, I, and J). Treatment with Gal-9 significantly reduces p27
Kip1 -and p21 Cip1 -positive podocytes (C, D, G, H, I, and J). Data are mean Ϯ SEM; *P Ͻ 0.01 versus db/m mice; **P Ͻ 0.01 versus db/db mice. To confirm that podocytes were positive for p27 Kip1 , we studied the expression of p27 Kip1 , nephrin, and type IV collagen using double immunofluorescence. p27 Kip1 -positive glomerular cells are observed mainly in extracapillary space and adjunct with capillary lining, which is visualized by nephrin and type IV collagen immunostaining (K). Arrowhead, p27
Kip1 -positive nucleus. Kip1 -and p21 Cip1 -positive cells predominantly increased in podocytes compared with nondiabetic db/m mice. Although the cell-cycle arrest and cellular hypertrophy in mesangial cells in diabetic nephropathy were well documented in the literature, we postulated that podocytes also are involved in such process. The administration of Gal-9 reduced p27
Kip1 -and p21 Cip1 -positive cells in glomeruli in db/db mice. The in vivo data suggested that Gal-9 ameliorated early diabetic nephropathy via inhibition of TGF-␤1 as well as cell-cycle-dependent pathways.
To confirm further the cell-cycle-dependent therapeutic mechanism of Gal-9 under high glucose condition, we used MPC (52) . Most of the standard cell culture methods induce Figure 7 . Effect of Gal-9 on high glucose induced the expression of p27
Kip1 and p21 Cip1 in MPC and MES. Gal-9 inhibits the protein expression of p27 Kip1 and p21 Cip1 in a dose-dependent manner, and maximum inhibition effect is observed at a concentration of 1 M revealed by Western blotting (A). We cultured differentiated MPC and MES. In MPC culture, DMEM that contained 0.5% FCS for 48 h and mature podocytes were incubated with NG, NGϩGal-9, HG, HGϩGal-9, and MN for 6 d. By Western blot analysis, protein levels of p27
Kip1 and p21
Cip1 increase in HG ambience compared with NG. By densitometric analysis, Gal-9 significantly suppresses p27
Cip1 (B). High glucose increases the mRNA level of TGF-␤1 without statistical significance, and Gal-9 shows no effect on the expression of TGF-␤1 mRNA (C). In MES culture, protein levels of p27 Kip1 and p21 Cip1 increase in HG ambience compared with NG, and treatment with Gal-9 shows an inhibitory effect on the protein expression of p27 Kip1 and p21 Cip1 without statistically significant differences (B). High glucose significantly increases the mRNA level of TGF-␤1, and Gal-9 showed minimal inhibition on the expression of TGF-␤1 mRNA (C). Data are mean Ϯ SEM; *P Ͻ 0.01 versus NG; **P Ͻ 0.01 versus HG. Figure 8 . Effect of Gal-9 on high-glucose-induced G1 cell-cycle arrest of MPC. We cultured differentiated MPC in DMEM that contained 0.5% FCS for 48 h, and mature podocytes were incubated with NG, NGϩGal-9, HG, HGϩGal-9, and MN for 6 d. The cell-cycle distribution of MPC was analyzed by laser scanning cytometer after staining with propidium iodide (A through D). HG increases cells in G0/G1 phase and decreases cells in S and G2 phases compared with cells in NG environment, meaning thereby that G0/G1-phase cell-cycle arrest is observed only in HG ambience. Addition of Gal-9 decreases G0/G1 population and increases cells in S and G2 phases. Data are mean Ϯ SEM; n ϭ 3.
cellular proliferation with the loss of differentiation and thus are not suitable for the investigation of high-glucose-induced G1-phase cell-cycle arrest. However, MPC, conditionally immortalized cells, cultured under successive permissive and nonpermissive conditions usually differentiate into mature podocyte and thus were considered suitable for this investigation. Using MPC on glass slides, we were able to measure total and peak intensity of propidium iodide fluorescence with generation of detailed images of the cell cycle in an unperturbed MPC population by laser scanning cytometry (53) . Gal-9 treatment normalized high-glucose-induced G1-phase cell-cycle arrest in MPC. Although nuclear condensation in M phase was observed, no apoptosis in MPC could be observed after Gal-9 treatment. However, Gal-9 dampened MPC hypertrophy because high-glucose-induced de novo protein synthesis was inhibited, leaving DNA replication unaltered. Because TGF-␤1 is not expressed abundantly in MPC and not altered by highglucose condition in our study and previous reports (54), Gal-9 has direct therapeutic effects on cell-cycle arrest in addition to TGF-␤1-mediated cell-cycle arrest. In MES culture, Gal-9 suppressed high-glucose-induced de novo synthesis of protein, p27 Kip1 and p21 Cip1 , and TGF-␤1 expression; however, the effects did not enter the statistically significant differences. This result will not negate the possibility that Gal-9 exerts the therapeutic potential by acting on mesangial cells. We speculated that mesangial cells in culture actively proliferate, and, unlike MPC, the mesangial cells did not well reflect the status of cellular hypertrophy in vivo in diabetic nephropathy.
In previous studies, Gal-9 induced apoptosis in various cells, including thymocytes and activated CD4 ϩ and CD8 ϩ T cells.
Gal-9 also acts as eosinophil chemoattractant (10) , and it suppresses apoptosis of eosinophil in eosinophilic patients, whereas it enhances apoptosis of eosinophils in normal volunteers (59) . In addition to such cells of immune system, recombinant Gal-9 induces apoptosis in human melanoma cell line (MM-RU) (60) . It is interesting that in cells of nonimmune origin, the expression of Gal-9 is upregulated by IFN-␥, for instance in human lung fibroblast cell line (61), umbilical vein endothelial cells (62) , and WM9 melanoma cells (17) . IFN-␥-induced Gal-9 has been implicated to exert an antitumor effect by inducing cell-cycle inhibition and apoptosis of malignant cells, and Gal-9 expression has been inversely correlated with progression of the disease in melanoma (60) . Thus, Gal-9 contributes to the elimination of antigen-activated T cells or various malignant cells to maintain proper homeostasis in cells and tissues (4) . We have shown that Gal-9 promotes and assists cell-cycle progression and successful replication in diabetic state, where cell-cycle progression is halted despite cell-cycle entry. Thus, Gal-9 exerts dual action on the cells and modulates the fate of cells, i.e., apoptosis subsequent to S-phase arrest or successful progression to G2 phase depending on the status or the nature of the cells. A similar scenario has been reported with Gal-1. Various cancer cells respond to Gal-1 by entering programmed cell death after S-phase cell-cycle arrest, whereas it causes no significant effect on normal cells and thus acts as a physiologic negative cell-cycle regulator with successful replication of the cells (15) . In renal hypertrophy in diabetes, Gal-9 inhibited glomerular TGF-␤1 expression and cell-cycle-dependent hypertrophy of the podocytes and mesangial cells by reducing p27 Kip1 and p21 Cip1 protein levels. We and others have already suggested that the recombinant soluble Gal-9 may have therapeutic potential in various diseases, such as autoimmune or allergic diseases (9) and malignancies (60) , in which it conceivably induces selective apoptosis of activated T cells and malignant cells, respectively. From the data of this investigation, one may suggest application of Gal-9 to control cell-cycle-dependent cellular hypertrophy, such as seen in glomerular cells in diabetes, cardiac muscle cells in hypertension, and smooth muscle cells in atherosclerosis. Finally, because Gal-9 recognizes various cell-surface glycoproteins in different cell types and in various cell cycle states, it may worthwhile also to identify such glycoproteins toward which blocking therapeutic interventions can be instituted.
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